EUVIMEDEUVIMED entdecken
Crossref

Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets

Diaa Shakleya, Bethel Asmelash, Alaadin Alayoubi, Nicolas Abrigo, Adil Mohammad, Jiang Wang, Jinhui Zhang, Jingyue Yang, Tim Andres Marzan, David Li, Maha Shaklah, Fahd M Alsharif und 8 weitere

Journal of Pharmaceutical Sciences · 2023-12 · 112 (12) · 3075-3087

DOI: 10.1016/j.xphs.2023.06.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023-12. Verfasst von Diaa Shakleya und 19 weiteren Autor:innen. Beteiligte Einrichtung: Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, 10903 New Ha…. Hauptthemen laut MEDLINE: Bumetanide, Nitrosamines, Caffeic Acids, Coumaric Acids. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitrosamine compounds are classified as potential human carcinogens, the origin of these impurities can be broadly classified in two categories, nitrosamine impurity found in drug products that are not associated with the Active Pharmaceutical Ingredient (API), such as N-nitrosodimethylamine (NDMA) or nitrosamine impurities associated with the API, such as nitrosamine drug substance-related impurities (NDSRIs). The mechanistic pathway for the formation of these two classes of impurities can be different and the approach to mitigate the risk should be tailored to address the specific concern. In the last couple of years number of NDSRIs have been reported for different drug products. Though, not the only contributing factor for the formation of NDSIRs, it is widely accepted that the presence of residual a nitrites/nitrates in the components used in the manufacturing of the drug products can be the primary contributor to the formation of NDSRIs. Approaches to mitigate the formation of NDSRIs in drug products include the use of antioxidants or pH modifiers in the formulation. The primary objective of this work was to evaluate the role of different inhibitors (antioxidants) and pH modifiers in tablet formulations prepared in-house using bumetanide (BMT) as a model drug to mitigate the formation of N-nitrosobumetanide (NBMT). A multi-factor study design was created, and several bumetanide formulations were prepared by wet granulation with and without sodium nitrite spike (100 ppm) and different antioxidants (ascorbic acid, ferulic acid or caffeic acid) at three concentrations (0.1%, 0.5% or 1% of the total tablet weight). Formulations with acidic and basic pH were also prepared using 0.1 N hydrochloric acid and 0.1 N sodium bicarbonate, respectively. The formulations were subjected to different storage (temperature and humidity) conditions over 6 months and stability data was collected. The rank order of N-nitrosobumetanide inhibition was highest with alkaline pH formulations, followed by formulations with ascorbic acid, caffeic acid or ferulic acid present. In summary, we hypothesize that maintaining a basic pH or the addition of an antioxidant in the drug product can mitigate the conversion of nitrite to nitrosating agent and thus reduce the formation of bumetanide nitrosamines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BumetanideNitrosaminesCaffeic AcidsCoumaric AcidsHumansAntioxidantsAscorbic AcidNitritesTablets

Stichwörter der Autor:innen

Ascorbic acidBumetanideCaffeic acidFerulic acidMitigationN-nitrosobumetanideNitriteStability

Substanzen

caffeic acidferulic acidBumetanideNitrosaminesAntioxidantsAscorbic AcidNitritesTabletsCaffeic AcidsCoumaric Acids

Autor:innen und Institutionen

  • Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. Electronic address: diaa…
  • Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of lifecycle Drug product, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
  • Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Zitieren

APA

Shakleya, D., Asmelash, B., Alayoubi, A., Abrigo, N., Mohammad, A., Wang, J., Zhang, J., Yang, J., Marzan, T. A., Li, D., Shaklah, M., Alsharif, F. M., Desai, S., Faustino, P. J., Ashraf, M., O'Connor, T., Vera, M., Raw, A., Sayeed, V. A., & Keire, D. (2023). Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets. Journal of Pharmaceutical Sciences, 112(12), 3075-3087. https://doi.org/10.1016/j.xphs.2023.06.013

Vancouver

Shakleya D, Asmelash B, Alayoubi A, Abrigo N, Mohammad A, Wang J, et al. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets. Journal of Pharmaceutical Sciences. 2023;112(12):3075-3087. doi:10.1016/j.xphs.2023.06.013

BibTeX
@article{Shakleya2023,
  author = {Shakleya, Diaa and Asmelash, Bethel and Alayoubi, Alaadin and Abrigo, Nicolas and Mohammad, Adil and Wang, Jiang and Zhang, Jinhui and Yang, Jingyue and Marzan, Tim Andres and Li, David and Shaklah, Maha and Alsharif, Fahd M and Desai, Saaniya and Faustino, Patrick J and Ashraf, Muhammad and O'Connor, Thomas and Vera, Matthew and Raw, Andre and Sayeed, Vilayat A and Keire, David},
  title = {Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2023},
  volume = {112},
  number = {12},
  pages = {3075--3087},
  doi = {10.1016/j.xphs.2023.06.013}
}
Kostenlos starten →